The open and transparent sharing of data on trials of COVID-19 treatments has the potential to accelerate the development of safe and effective medicines and vaccines against the coronavirus.

Vivli, the Center for Clinical Research Data, is to launch a web portal for the sharing of data on completed COVID-19 interventional treatment trials.

All member and user fees for accessing and sharing the data would be waived.

This initiative is part of Vivli’s commitment to serve the open science community.

Vivli’s Executive Director Rebecca Li said that open and transparent sharing of clinical trials data is the best way to develop safe and effective medicines and vaccines.

In an article published in “Science,” Vivli co-founder and UCSF professor Ida Sim and her co-authors called on the National Institutes of Health (NIH) to strengthen its Draft Data Sharing Policy.

The authors of the article also recommended policies that the NIH can adopt to transform academic culture and promote the practice of routine data sharing.

KEY POINTS

1. Vivli is to launch a portal to facilitate the data sharing on COVID-19 treatment trials.
2. Member and user fees for the portal would be waived.
3. Vivli co-founder Ida Sim and other data transparency leaders called on the NIH to strengthen its policy on data sharing.

“I am delighted to see us do all that we can to advance the knowledge around the COVID-19 pandemic. COVID-19 trials should be made open to all researchers so that no stone is left unturned in reviewing and analyzing the data,” says Vivli co-founder Ida Sim.

Article source: https://bit.ly/2V0Nva9
Image source:https://a-m-i-ltd.com/contact/

#ClinicalTrials, #COVID-19, #ClinicalData, #DataSharing, #ClinicalResearch, #ClinicalResearchData, #Vivli

P.S. Staying up-to-date with what’s new in Clinical Trials? Get the latest articles summarized and delivered free to your e-mail inbox. Click here to learn more.